Perrigo Bolsters US Generics Ahead Of Separation Plans
Signed Eighth Agreement With Sol-Gel To Further Expand Partnership
Executive Summary
Perrigo has expanded its agreement with Sol-Gel Technologies to cover ten products, shortly after warning that plans to separate the firm’s Prescription Pharmaceuticals US generics unit “in the short term” would likely “destroy shareholder value.”
You may also be interested in...
Perrigo And Sol-Gel Face Up To Duobrii Lawsuit
Collaboration partners Perrigo and Sol-Gel Technologies face legal action stemming from Perrigo’s filing of an ANDA for generic Duobrii lotion for the treatment of plaque psoriasis in adults.
Rosemont Deal Shows Value Is Out There For US Exit, Perrigo Says
Perrigo management provided colorful commentary on Perrigo’s latest endeavors to separate the company’s US generics business, following the recent sale of Perrigo’s Rosemont Pharmaceuticals subsidiary for an “attractive” multiple.
Deal Watch: Merck's Busy Stretch Includes Collaborations With Dewpoint, Zymeworks
Bristol makes its own deal with Celgene ally Dragonfly, while Gilead ends virology partnerships with Durect and Precision BioSciences.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: